Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CRHBP | P24387 | 2/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA4 | P22748 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412497 | 1.00 | KEAP1 (1.00) | KEAP1ITGB2ICAM1ITGALGRIA2 | |
| SCHEMBL29295542 | 0.76 | KEAP1 (0.61) | KEAP1GRIA2PIK3C3CA12CA1 | |
| SCHEMBL20617339 | 0.76 | KEAP1 (0.61) | KEAP1GRIA2CA12CA1CA2 | |
| SCHEMBL9696686 | 0.76 | KEAP1 (0.61) | KEAP1PIK3C3CA12CA1CA2 | |
| SCHEMBL3993214 | 0.76 | KEAP1 (0.61) | KEAP1GRIA2LMNAHTTPIK3C3 | |
| SCHEMBL16852809 | 0.76 | KEAP1 (0.61) | KEAP1PIK3C3 | |
| SCHEMBL755596 | 0.76 | KEAP1 (0.61) | KEAP1LMNAHTTPIK3C3CA12 | |
| SCHEMBL1776074 | 0.76 | KEAP1 (0.61) | KEAP1GRIA2PIK3C3CA12CA1 | |
| SCHEMBL30016008 | 0.76 | KEAP1 (0.61) | KEAP1GRIA2LMNAHTTPIK3C3 | |
| SCHEMBL753235 | 0.76 | KEAP1 (0.60) | KEAP1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116669744-A | Nrf2 activating compounds | 千寿制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-13 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10703755-B2 | Substituted purine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| JP-2013537216-A | — | — | 2013-09-30 | — | — | JP | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1054877-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041246-A1 | NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 4340/4885ICAM1 4670/4885 |
| US-20150218187-A1 | SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DGAT1, DGAT2, CPT1A | KEAP1 1100/4885ITGB2 3197/4885ICAM1 3058/4885 |
| US-11059816-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 3785/4885ICAM1 4488/4885 |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 4340/4885ICAM1 4670/4885 |
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 3682/4885ICAM1 4225/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 3682/4885ICAM1 4225/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | KEAP1 1057/4885ITGB2 1856/4885ICAM1 3954/4885 |
| US-20200071317-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KEAP1 2/4885ITGB2 3785/4885ICAM1 4488/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | KEAP1 357/4885ITGB2 3314/4885ICAM1 3809/4885 |
| US-10703755-B2 | Substituted purine derivative | TLR7, TLR9, TLR1 | KEAP1 3091/4885ITGB2 4565/4885ICAM1 4287/4885 |
| US-20190169191-A1 | SUBSTITUTED PURINE DERIVATIVE | TLR7, TLR9, TLR1 | KEAP1 3091/4885ITGB2 4565/4885ICAM1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.